| TFF1 |
DSS-induced colitis |
Systemic |
Homodimer effective and
acts in synergy in with EGF; monomer ineffective |
(158) |
| DSS-induced colitis or IL-10–/– mouse |
Intragastric administration
of TFF secreting L. lactis; rectal or oral administration |
Improved chronic colitis
in IL-10–/– mouse; prevention and healing
of chronic DSS-induced colitis; In situ synthesis
by L. lactis is more effective than rectally and
orally administered. |
(20) |
| Radiation-induced oral mucositis |
Mouth rinse formulation
of TFF1-secreting L. lactis
|
Safe and efficient for prevention
and treatment of oral mucositis |
(156) |
| |
|
|
|
|
| TFF2 |
Indomethacin-induced gastric damage |
Subcutaneous or oral |
Cytoprotection subcutaneously
administrated but ineffective via oral administration |
(31) |
| Aspirin-induced
gastric
injury |
Intragastric |
Prevents damage but fails
to stimulate early restitution |
(178) |
| Ethanol- or
indomethacin-induced
gastric injury |
Gastric
lavage or intraperitoneal |
Protection via oral but
not intraperitoneal |
(23) |
| DSS-induced colitis |
Subcutaneous or intracolonic |
Ameliorated the clinical
course of colitis in a preventive mode but not for treatment; topical
administration superior to systemic administration |
(90) |
| DNBS-induced
colitis |
Intrarectal |
Enhancement of colonic epithelial
repair and reduction of inflammation |
(21) |
| DSS- or mitomycin-induced colitis |
Intracolonic or subcutaneous |
Luminal positive effect
only on DSS-induced colitis; injected aggravated colitis in both models |
(44) |
| DSS-induced colitis or IL-10–/– mouse |
Intragastric administration
of TFF-secreting L. lactis
|
Improved chronic colitis
in IL-10–/– mouse; effective in the prevention
and healing of chronic DSS-induced colitis |
(20) |
| Indomethacin-induced
gastric
damage or mercaptamine-induced duodenal ulcers |
Subcutaneous infusion or
oral |
Accelerated
gastric ulcer
healing but aggravated duodenal ulcer |
(179) |
| |
|
|
|
|
| TFF3 |
Acetic acid-induced
colitis |
Rectal instillation |
Enhanced epithelial migration
and reconstitution of normal healing |
(22) |
| Chemotherapy-
or radiation-induced
intestinal mucositis |
Oral gavage |
Improved
mucolitis and mucosal
permeability; reduced ongoing apoptosis |
(177) |
| Ethanol- or
indomethacin-induced
gastric injury |
Gastric
lavage or intraperitonial |
Preventive |
(23) |
| DSS-induced
colitis |
Systemic |
Moderate effect attenuating
the disease |
(73) |
| DSS- or mitomycin-induced
colitis |
Intracolonic
or subcutaneous |
Injected
aggravated colitis;
luminal administration of dimer improved both models; monomer ineffective
in both models |
(44) |
| DSS-induced colitis and
IL-10–/– mouse |
Intragastric administration
of TFF-secreting L. lactis
|
Improved chronic colitis
in IL-10–/– mouse; effective in the prevention
and healing of chronic DSS-induced colitis |
(20) |
| Ethanol-induced gastric mucosal damage |
Gastric gavage |
Prevented/ameliorated gastric
mucosal injury |
(40) |
| Burn-induced intestinal
mucosa injury |
Gene
therapy |
Alleviated
and accelerated
reconstruction of the damaged mucosa |
(180) |
